 Home > Active Ingredient News > Blood System > HAEMATOLOGICA: Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving single-agent akarabutinib: a pooled analysis of 762 patients.

HAEMATOLOGICA: Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving single-agent akarabutinib: a pooled analysis of 762 patients.

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

cardiac hypertrophy causes

total

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bruton Tyrosine Kinase (BTK) inhibitor by Lu imatinib therapy is associated with significant cardiac blood vessels associated toxicity, which may be due to off-target kinase inhibiting cardiovascular (CV) of such toxicity may limit an effective therapy in chronic lymphocytic leukemia (CLL) Use in patients
.

Acarabutinib is a second-generation BTK inhibitor with higher BTK selectivity

This analysis characterizes the data of CV adverse events (AEs) in CLL patients who received acarabutinib monotherapy in clinical trials (NCT02029443; NCT02475681; NCT02970318; NCT02337829)
.

Oral acarabutinib with a total daily dose of 100-400 mg, then converted to 100 mg twice a day, and continued until disease progression or toxicity

This analysis characterizes the data of CV adverse events (AEs) in CLL patients who received acarabutinib monotherapy in clinical trials (NCT02029443; NCT02475681; NCT02970318; NCT02337829)

91% of patients with cardiac AEs had CV risk factors before treatment with acalabrutinib

Overall, these data indicate that acarabutinib has a lower incidence of new cardiac ae in CLL patients

Original source:

Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR.

Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Haematologica; https://doi.
org/10.
3324/haematol.
2021.
278901 [Early view].
Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P , Stephens DM, Sun C, Jurczak W, leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.